



Bartonella quintana and *Bartonella vinsonii* subsp. *vinsonii* bloodstream co-infection in a girl from North Carolina, USA

Edward B. Breitschwerdt¹ · Ricardo G. Maggi¹

Received: 9 August 2018 / Accepted: 18 September 2018 / Published online: 24 September 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

The genus *Bartonella* consists of globally distributed and highly diverse alpha-proteobacteria that infect a wide-range of mammals. Medically, *Bartonella* spp. constitute emerging, vector-borne, zoonotic, intravascular organisms that induce long-lasting bacteremia in reservoir-adapted (passive carrier of a microorganism) hosts. At times, these bacteria are accidentally transmitted by animal scratches, bites, needles sticks or vectors to animal or human hosts. We report the first documented human case of blood stream infection with *Bartonella vinsonii* subsp. *vinsonii* in a girl from North Carolina, USA, who was co-infected with *Bartonella quintana*. Limitations of *Bartonella* spp. serology and the challenges of microbiological culture and molecular diagnostic confirmation of co-infection with more than one *Bartonella* spp. are discussed. When and where these infections were acquired is unknown; however, exposure to rodents, fleas and cats in the peri-equestrian environment was a suspected source for transmission of both organisms.

Keywords *Bartonella quintana* · *Bartonella vinsonii* subsp. *vinsonii* · Bacteria · Vector · Equestrian

Introduction

During the past two decades, there has been increasing scientific interest in the genus *Bartonella*, in conjunction with an increasing medical emphasis on the seemingly diverse spectrum of cardiovascular, neurological and rheumatologic disease manifestations that can result from persistent bloodstream infection with these bacteria in animals and humans [1–3]. Historically, *Bartonella quintana*, the cause of Trench Fever in World War I, has been more recently referred to as Urban Trench Fever, most often infecting homeless individuals with human body louse exposure [2]. *Bartonella vinsonii* subsp. *vinsonii* was isolated from voles during the 1940s by James Baker, Veterinary Corps, U.S. Army, while stationed at the War Disease Control Station at Grosse Isle, Quebec Province, Canada [4]. The organism was named in honor of J. William Vinson, who along with Henry S. Fuller first determined that *Bartonella* spp. could occasionally be

isolated on blood agar plates. Subsequently, *B. vinsonii* subsp. *berkhoffii* [5], *B. vinsonii* subsp. *arupensis* [6], and *B. vinsonii* subsp. *yucatanensis* [7] were described in 1996, 1998, and 2016, respectively. Infection with *B. vinsonii* subsp. *berkhoffii* and *B. vinsonii* subsp. *arupensis* have been previously reported in association with human illnesses [8, 9], but to our knowledge, infection with *B. vinsonii* subsp. *vinsonii* has not been reported in a human being.

Materials and methods

Case report

In September 2017, the mother of a 14-year-old Caucasian female contacted our research group requesting that her daughter be tested for evidence of *Bartonella* spp. bloodstream infection. With signed parental permission, the child was entered into North Carolina State University Institutional Review Board (IRB) Protocol #1960, Detection of *Bartonella* species in the blood of healthy and sick people with animal contact or arthropod exposures. Based upon responses to our IRB research questionnaire, the girl's historical duration of illness was 5 years, during which time she had experienced intermittent fever, ocular pain,

✉ Edward B. Breitschwerdt
ed_breitschwerdt@ncsu.edu

¹ Intracellular Pathogens Research Laboratory, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr., Raleigh, NC 27607, USA

balance problems, headaches, irritability, blurred vision, mental confusion, disorientation, hallucinations, memory loss, insomnia, tremors, anxiety and panic attacks. Other listed symptoms included fatigue, joint pain involving the elbows, shoulders, hips, knees and ankles, muscle weakness and pain, tachycardia and diarrhea. During the course of illness, the severity, frequency and number of symptoms progressively increased. Historically, the girl was an avid equestrian (riding nearly every day of the week), had dog and horse exposure for the past 5 years, and had traveled throughout the United States and to Europe. Vector exposure was reported for mosquitoes and ticks. There was no historical exposure to pet rodent species.

Prior diagnostic testing had been performed by her pediatrician, ear, nose and throat specialist, and allergist. Previous diagnoses listed by the parents on the research questionnaire had included ADHD (Attention Deficit Hyperactivity Disorder), migraines, allergies to dairy products, gluten, and oak tree pollen, auditory processing disorder, learning disability (reading), *Clostridium difficile* colitis and “neuroimmune disorder” (myalgic encephalomyelitis). Repeated physical examinations were unremarkable. White blood cell counts, ranging from 3.3 to $5.5 \times 10^3/\mu\text{L}$, were often low despite a concurrent fever. Serial biochemical and urinalyses results were normal. IgA, IgM, IgE and IgG immunoglobulin subclass values were age appropriate. Extensive viral, protozoal, and bacterial (including *Borrelia burgdorferi*) testing was either unremarkable or diagnostically inconclusive. *Mycoplasma pneumoniae* IgG and Coxsackie A&B subtype antibody titers were at times increased.

Beginning in September 2016, osteopathic treatments consisted of manipulation, neuromuscular reeducation, vitamin C, MgCl supplementation, iodine, melatonin, and herbal dietary supplements. Due to ongoing symptoms, doxycycline and cefuroxime were administered in October 2016. In January 2017, a commercial diagnostic laboratory (Galaxy Diagnostics Inc. Research Triangle Park, NC) reported a *B. quintana* serum indirect fluorescent antibody (IFA) titer of 1:64, after which her physician administered doxycycline, rifampin, and clarithromycin for 2 months. Again, antibiotic administration resulted in only minimal symptomatic improvement.

***Bartonella* spp. serology and enrichment blood culture/PCR testing**

Upon entry into our research study in September 2017, blood and serum specimens were obtained aseptically on September 21st and 22nd for *Bartonella* spp. indirect fluorescent antibody serology and BAPGM (*Bartonella* alpha proteobacteria growth medium) enrichment blood culture/PCR testing. Previously described indirect fluorescent antibody serology assays [10, 11, 15] were used to test the girl’s serum

sample. In addition, *B. quintana* (NCSU 11-MO-01, Monkey origin) organisms were passed from 5% sheep blood agar into cell lines to obtain antigens for IFA testing as described previously [12]. For all six IFA assays, heavily infected cell cultures were spotted onto 30-well Teflon coated slides (Cel-Line/Thermo Scientific, Waltham, MA), air dried, acetone fixed and stored frozen until tested. Serum samples were diluted in phosphate buffered saline (PBS, pH 7.4) containing normal goat serum, Tween-20 and 0.5% of powdered nonfat dry milk to block non-specific antigen binding sites. Sera were tested at dilutions of 1:16–1:8192. Serum that was reactive to all six antigens and a non-seroreactive serum to all antigens were run concurrently with the girl’s serum at two independent testing time points.

BAPGM enrichment blood culture, DNA extraction, and DNA sequencing methods were performed as previously described [10, 11]. Quantitative PCR targeting of the *Bartonella* ITS region was performed using oligonucleotides BspITS325s: 5' CCT CAG ATG ATG ATC CCA AGC CTT CTG GCG 3' and BspITS543as: 5' AAT TGG TGG GCC TGG GAG GAC TTG 3' as forward and reverse primers, respectively, and oligonucleotides BspITS438probe: 5' FAM-GGT TTT CCG GTT TAT CCC GGA GGG C-BHQ1 3' and BspITS438Rprobe: 5' CY5-AGG AAG GTT TTT ACC RAT TTA CTC CTG AGG- IowaBlack3' as taqman probes. Amplification was performed in a 25 μL final volume reaction containing 12.5 μL of SsoAdvanced™ Universal Probes Supermix (Bio-Rad Laboratories, USA), 0.2 μL of 100 μM of each forward primer, reverse primer, and taqman probe (Integrated DNA Technologies, INC., IDT® DNA Technology, Skokie, Illinois), 7.5 μL of molecular-grade water, and 5 μL of DNA from each sample tested. PCR negative controls were prepared using 5 μL of DNA from the blood of a healthy dog. Positive controls for PCR were prepared using 5 μL of DNA from a serial dilution (using dog blood DNA) of *B. henselae* genomic DNA equivalent to 0.1, 0.01, and 0.001 pg/ μL . Quantitative PCR was performed in an CFX96® (Bio-Rad Laboratories, USA) thermocycler under the following conditions: a single hot-start cycle at 95 °C for 3 min followed by 45 cycles of denaturing at 94 °C for 10 s, annealing at 68 °C for 10 s, and extension at 72 °C for 10 s. Amplification was completed by an additional cycle at 72 °C for 30 s. Positive amplification was assessed by analysis of detectable fluorescence by cycle values at Channel 1 and Channel 4. All qPCR positive amplicon products were sent to a commercial laboratory (Genewiz, Research Triangle Park, NC) for DNA sequencing. Bacteria species and strain were defined by comparing similarities with other sequences deposited in the GenBank database using the Basic Local Alignment Search Tool (Blast v. 2.0), and an in-house curated database.

Also, each DNA extraction was tested with *B* spp. *groEL*-20 s (5' CGTGAAGTTGCTTCTAAAACCAATGACATT

G 3') and *B* spp. *groEL*-590as (5' CGAGSGTTGCCAAA GCTTCACCTTC 3') and with *B* spp. *gltA*-850 s (5' AGA ATTCCTGAATTYATTGCACGTGCAAAAAG 3') and *B* spp. *gltA*-1120as (5' CCTAGAGCTTTTAATGTAATW CCAGAATAGAAATC 3') primers, respectively, that were previously validated to amplify *Bartonella* spp. DNA in our laboratory (unpublished data).

Results

By qPCR targeting the 16S-23S ITS region, *B. quintana* DNA was PCR amplified and sequenced from the girl's blood DNA extraction and *B. vinsonii* subsp. *vinsonii* DNA was amplified and sequenced from a 14-day BAPGM enrichment blood culture. There was no agar plate bacterial growth following subculture from the liquid enrichment medium at 7, 14, or 21 days. The *B. quintana* ITS sequence was 100% similar to GenBank accession DQ648598. The *B. vinsonii* subsp. *vinsonii* DNA sequence was 100% similar to BAO16SRC. Comparative 16S-23S ITS DNA sequences for *B. quintana*, *B. vinsonii* subsp. *vinsonii* and other selected *Bartonella* spp. or subsp. ranging from 79 to 93% are provided in Table 1. PCR testing of all blood, serum and enrichment culture specimens targeting *groEL* and *gltA* genes failed to result in amplification. By IFA testing, her *B. quintana*, *B. henselae*, *B. vinsonii* subsp. *berkhoffii* genotypes I, II and III, and *B. koehlerae* antibody titers were 1:32, 1:32, < 1:16, < 1:16, < 1:16, and < 1:16, respectively (with a non-reactive or negative titer being < 1:64). Identical IFA titers were obtained when the serum was tested at a later time point. *Bartonella vinsonii* subsp. *vinsonii* IFA slides were not available for genotype serological testing.

Phylogenetic analyses using the short DNA sequences amplified from blood or BAPGM enrichment blood culture further supported co-infection with *B. quintana* and *B. vinsonii* subsp. *vinsonii* (Fig. 1). In an effort to further

assess qPCR gene target sequence similarities among rodent isolates of the *B. vinsonii* subsp. complex, the analogous region of the *Bartonella* 16S-23S rRNA gene from isolates derived from white-throated woodrats (*Neotoma albigula*) captured in New Mexico (NA789) and Colorado (NA251), from the Pinyon mouse, *Peromyscus truei* (PT719) captured in New Mexico, from the deer mouse (*Peromyscus maniculatus*) [PM370] and brush mouse *Peromyscus boylii* (PB230) captured in Colorado were kindly provided by Dr. Michael Kosoy, Centers for Disease Control and Prevention, Fort Collins, Colorado. The *B. vinsonii* subsp. *vinsonii* qPCR DNA sequence from the girl differed from the five rodent isolates from Colorado and New Mexico, but was 100% similar to the type strain of *B. vinsonii* subsp. *vinsonii* (GenBank accession BAO16SRC), the Baker isolate type strain that originated from Grosse Isle, Quebec Province, Canada.

Consistent with Institutional Review Board requirements, serology and PCR research results were communicated to the girl's attending physician for consideration during future clinical assessments.

Discussion

Using targeted qPCR amplification and DNA sequencing, we confirmed co-infection with two *Bartonella* spp.; *B. quintana* in blood and *B. vinsonii* subsp. *vinsonii* in a 14-day enrichment blood culture, in a girl with historically unexplained symptomatology. *Bartonella* spp. co-infections have been reported infrequently, and to our knowledge only in sick individuals with high exposure risks (i.e., frequent arthropod or animal contact) [15–17]. Due to low bacterial numbers, blood culture isolation of a *Bartonella* spp. is rarely achieved in research intensive or diagnostic clinical settings [17, 18]. PCR using DNA extracted following enrichment culture in insect biochemical growth media [19, 20] or the

Table 1 Number and percentage of bases comparing the 16S-23S intergenic spacer region DNA sequence similarities for *Bartonella quintana* and *Bartonella vinsonii* subsp. *vinsonii* to other selected *Bartonella* species or subspecies

	Sample # 11,241 (blood)	Sample # 11,242 (C14 enrichment blood culture)
<i>Bartonella quintana</i> (DQ648598)	167/167 (100%)	133/167 (80%)
<i>Bartonella v. vinsonii</i> (BAO16SRC)	132/167 (79%)	167/167 (100%)
<i>Bartonella v. arupensis</i> (JN402327)	135/167 (81%)	155/167 (93%)
<i>Bartonella henselae</i> Houston-I (CP020742)	135/167 (81%)	136/167 (81%)
<i>Bartonella koehlerae</i> (AF312490)	135/167 (81%)	135/167 (81%)
<i>Bartonella v. berkhoffii</i> genotype I (DQ059762)	136/167 (81%)	149/167 (89%)
<i>Bartonella v. berkhoffii</i> genotype II (DQ059763)	135/167 (81%)	145/167 (87%)
<i>Bartonella v. berkhoffii</i> genotype III (DQ059764)	136/167 (81%)	149/167 (89%)
<i>Bartonella v. berkhoffii</i> genotype IV (DQ059765)	135/167 (81%)	145/167 (87%)

v. vinsonii subsp

consequences of accidental, ecological spillover of one or more *Bartonella* spp. into a non-reservoir adapted human host remains unclear and incompletely investigated [1–3, 28]. However, on the basis of evolving comparative microbiological and pathological data, *Bartonella* spp. may be a historically unsuspected cause or cofactor in a spectrum of cardiovascular, neurological and rheumatological diseases in animals and human patients [3, 11, 15, 17]. Similar to the medical history reported in this girl, investigators in France have reported longstanding, non-specific symptoms in conjunction with bloodstream infection with known and previously undescribed *Bartonella* spp. in humans [17]. The girl in this report experienced symptoms most indicative of neurological (headache, irritability, blurred vision, mental confusion, disorientation, hallucinations, memory loss) and rheumatological (pain involving multiple joints) diseases. Our research group has focused primarily on testing animal health workers, who often experience frequent exposures to arthropods and infected animals [12–16, 31, 32]. We suggest that animal health workers and others with extensive arthropod and animal contact will become the sentinel populations by which the microbiological and medical relevance of bartonellosis is more thoroughly defined. Due to similarities in *Bartonella* spp. associated pathology among animals, particularly dogs and humans, we and others have proposed a comparative One Health approach to better clarify the medical importance of the genus *Bartonella* [1–3, 33].

As the isolation and PCR detection of rodent, bat and other reservoir-adapted *Bartonella* spp. from human blood lacks sensitivity, infection may occur more frequently than has been historically suspected [34, 35]. For example, studies from Thailand, Nigeria, the United States and other countries, have documented human infections with *Bartonella* spp. that are genetically similar to those found in regional rodents [35–37]. Rodents, the primary reservoir hosts for *B. vinsonii* subsp. *arupensis*, *B. vinsonii* subsp. *vinsonii* and *B. vinsonii* subsp. *yucatanensis* are most likely infected by fleas or other hematophagous arthropod vectors [6, 36, 38]. Recent studies from northern Mexico and the Yucatan ecosystem found up to 58% of *Peromyscus yucatanicus* (deer mice) and other *Peromyscus* spp. were infected with *B. vinsonii* subsp. *vinsonii* or *B. vinsonii* subsp. *yucatanensis* [7, 36, 37]. These and other studies illustrate the high prevalence of bacteremia found among many rodent reservoir hosts. Based upon comparative host–pathogen co-evolutionary analyses, *Bartonella* spp., unlike comparative analyses of *Leptospira* spp., have co-evolved with bats, rodents and other mammals, with minimal evolutionary host switching [37]. It is possible that exposure to peridomestic rodents or rodent fleas, potentially at an equestrian center, could have been the source of the girl's *B. vinsonii* subsp. *vinsonii* and *B. quintana* infections. Cats, dogs, horses, humans and rodents and their associated arthropod vectors are all

commonly found around equestrian stables and farms. In 2007, we reported *B. quintana* blood stream infection in an equestrian instructor from North Carolina and in the blood of the feral cat that most likely infected her with *B. quintana* via a bite wound [39]. Other equestrian case-based [40] and epidemiological studies [41] have reported potential associations between *Bartonella* spp. exposures with cattle and horse farms. Whether infection with *B. quintana* and *B. vinsonii* subsp. *vinsonii* were transmitted to this girl simultaneously or sequentially, and the extent to which co-infection may have contributed to the girl's historical symptoms could not be determined.

Acknowledgements This study was supported in part by the state of North Carolina and donations to the North Carolina State University College of Veterinary Medicine Foundation fund for Bartonella/Vector Borne Disease Research. The authors thank Julie M. Bradley, Intracellular Pathogens Research Laboratory, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, for technical assistance.

Compliance with ethical standards

Conflict of interest E.B.B., in conjunction with Sushama Sontakke and North Carolina State University, holds US Patent No. 7,115,385, Media and Methods for Cultivation of Microorganisms, which was issued October 3, 2006. E.B.B. is a founder, shareholder and the chief scientific officer for Galaxy Diagnostics, a company that provides diagnostic testing for the detection of *Bartonella* species and other vector borne pathogens in animals and human patients. R.G. Maggi has lead research efforts to optimize the BAPGM platform and is the scientific technical advisor for Galaxy Diagnostics.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. North Carolina State University (NCSU) Institutional Review Board provided (IRB 1960) ethical approval for this study.

Informed consent Informed consent was obtained from the parents of the participant included in this study.

References

1. Iannino F, Salucci S, Di Provvido A, Paolini A, Ruggieri E (2018) Bartonella infections in humans dogs and cats. *Vet Ital* 54:63–72
2. Regier Y, O'Rourke F, Kempf VA (2016) *Bartonella* spp.—a chance to establish One Health concepts in veterinary and human medicine. *Parasit Vectors* 9:261
3. Breitschwerdt EB. Bartonellosis (2014) One health perspectives for an emerging infectious disease. *ILAR J* 55:46–58
4. Baker JA A rickettsial infection in Canadian voles. *J. Exp. Med.* 1946; 84:37–51
5. Kordick DL, Swaminathan B, Greene CE, Wilson KH, Whitney AM, O'Connor S, Hollis DG, Matar GM, Steigerwalt AG, Malcolm GB, Hayes PS, Hadfield TL, Breitschwerdt EB, Brenner DJ (1996) *Bartonella vinsonii* subsp. *berkhoffii* subsp. nov., isolated

- from dogs; *Bartonella vinsonii* subsp. *vinsonii*; and emended description of *Bartonella vinsonii*. Int J Syst Bacteriol 46:704–709
6. Hofmeister EK, Kolbert CP, Abdulkarim AS, Magera JM, Hopkins MK, Uhl JR, Ambyaye A, Telford SR 3rd, Cockerill FR 3rd, Persing DH (1998) Cosegregation of a novel *Bartonella* species with *Borrelia burgdorferi* and *Babesia microti* in *Peromyscus leucopus*. J Infect Dis 177:409–416
 7. Schulte Fishedick FB, Stuckey MJ, Aguilar-Setién A, Moreno-Sandoval H, Galvez-Romero G, Salas-Rojas M, Arechiga-Ceballos N, Overgaauw PA, Kasten RW, Chomel BB (2016) Identification of *Bartonella* Species Isolated from Rodents from Yucatan, Mexico, and Isolation of *Bartonella vinsonii* subsp. *yucatanensis* subsp. nov. Vector Borne Zoonotic Dis 16:636–642
 8. Roux V, Eykyn SJ, Wyllie S, Raoult D (2000) *Bartonella vinsonii* subsp. *berkhoffii* as an agent of afebrile blood culture-negative endocarditis in a human. J Clin Microbiol 38:1698–1700
 9. Fenollar F, Sire S, Raoult D (2005) *Bartonella vinsonii* subsp. *arupensis* as an agent of blood culture-negative endocarditis in a human. J Clin Microbiol 43:945–947
 10. Oteo JA, Maggi R, Portillo A, Bradley J, García-Álvarez L, San-Martín M, Roura X, Breitschwerdt E (2017) Prevalence of *Bartonella* spp. by culture, PCR and serology, in veterinary personnel from Spain. Parasit Vectors 10:553
 11. Lantos PM, Maggi RG, Ferguson B, Varkey J, Park LP, Breitschwerdt EB, Woods CW (2014) Detection of *Bartonella* species in the blood of veterinarians and veterinary technicians: a newly recognized occupational hazard? Vector Borne Zoonotic Dis 14:563–570
 12. Hegarty BC, Bradley JM, Lappin MR, Balakrishnan N, Mascarelli PE, Breitschwerdt EB (2014) Analysis of seroreactivity against cell culture-derived *Bartonella* spp. antigens in dogs. J Vet Intern Med 28:38–41
 13. Tamura K, Nei M (1993) Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10:512–526
 14. Kumar S, Stecher G, Tamura K (2016) MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol 33:1870–1874
 15. Mozayani BR, Maggi RG, Bradley JM, Breitschwerdt EB (2018) Rheumatological presentation of *Bartonella koehlerae* and *Bartonella henselae* bacteremias: a case report. Medicine (Baltimore) 97:e0465
 16. Maggi RG, Mascarelli PE, Pultorak EL, Hegarty BC, Bradley JM, Mozayani BR, Breitschwerdt EB (2011) *Bartonella* spp. bacteremia in high-risk immunocompetent patients. Diagn Microbiol Infect Dis 71:430–437
 17. Vayssier-Taussat M, Moutailler S, Féménia F, Raymond P, Croce O, La Scola B, Fournier PE, Raoult D (2016) Identification of Novel Zoonotic Activity of *Bartonella* spp., France. Emerg Infect Dis 22:457–462
 18. Kwon HY, Park YK, Lee SM, Baek JH, Kang JS, Chung MH, Kim EJ, Lee JS (2018) Characterization of clinical isolates of *Bartonella henselae* Strains, South Korea. Emerg Infect Dis 24:912–915
 19. Duncan AW, Maggi RG, Breitschwerdt EB (2007) A combined approach for the enhanced detection and isolation of *Bartonella* species in dog blood samples: pre-enrichment culture followed by PCR and subculture onto agar plates. J Microbiol Meth 69:273–281
 20. Riess T, Dietrich F, Schmidt KV, Kaiser PO, Schwarz H, Schäfer A, Kempf VA (2008) Analysis of a novel insect cell culture medium-based growth medium for *Bartonella* species. Appl Environ Microbiol 74:5224–5227
 21. La Scola B, Raoult D (1999) Culture of *Bartonella quintana* and *Bartonella henselae* from human samples: a 5-year experience (1993 to 1998). J Clin Microbiol 37:1899–1905
 22. Lynch T, Iverson J, Kosoy M (2011) Combining culture techniques for *Bartonella*: the best of both worlds. J Clin Microbiol 49:1363–1368
 23. Pultorak EL, Maggi RG, Mascarelli PE, Breitschwerdt EB (2013) Serial testing from a 3-day collection period by use of the *Bartonella* Alphaproteobacteria growth medium platform may enhance the sensitivity of *Bartonella* species detection in bacteremic human patients. J Clin Microbiol 51:1673–1677
 24. Varanat M, Maggi RG, Linder KE, Breitschwerdt EB (2011) Molecular prevalence of *Bartonella*, *Babesia*, and hemotropic *Mycoplasma* sp. in dogs with splenic disease. J Vet Intern Med 25:1284–1291
 25. Donovan TA, Balakrishnan N, Carvalho Barbosa I, McCoy T, Breitschwerdt EB, Fox PR (2018) *Bartonella* spp. as a possible cause or cofactor of feline endomyocarditis-Left ventricular endocardial fibrosis complex. J Comp Path 162:29–42
 26. Viezens J, Arvand M (2008) Simultaneous presence of two different copies of the 16S rRNA gene in *Bartonella henselae*. Microbiology 154:2881–2886
 27. Kosoy M, McKee C, Albayrak L, Fofanov Y (2018) Genotyping of *Bartonella* bacteria and their animal hosts: current status and perspectives. Parasitology 145:543–562
 28. Okaro U, Addisu A, Casanas B, Anderson B (2017) *Bartonella* species, an emerging cause of blood-culture-negative endocarditis. Clin Microbiol Rev 30:709–746
 29. Pitassi LH, de Paiva Diniz PP, Scorpio DG, Drummond MR, Lania BG, Barjas-Castro ML, Gilioli R, Colombo S, Sowy S, Breitschwerdt EB, Nicholson WL, Velho PE (2015) *Bartonella* spp. bacteremia in blood donors from Campinas, Brazil. PLoS Negl Trop Dis 9:e0003467
 30. Diniz PP, Velho PE, Pitassi LH, Drummond MR, Lania BG, Barjas-Castro ML, Sowy S, Breitschwerdt EB, Scorpio DG (2016) Risk factors for bartonella species infection in blood donors from Southeast Brazil. PLoS Negl Trop Dis 10:e0004509
 31. Breitschwerdt EB, Maggi RG, Nicholson WL, Cherry NA, Woods CW (2008) *Bartonella* sp. bacteremia in patients with neurological and neurocognitive dysfunction. J Clin Microbiol 46:2856–2861
 32. Kaufman DL, Kogelnik AM, Mozayani RB, Cherry NA, Breitschwerdt EB (2017) Neurological and immunological dysfunction in two patients with *Bartonella henselae* bacteremia. Clin Case Rep 5:931–935
 33. Breitschwerdt EB, Linder KL, Day MJ, Maggi RG, Chomel BB, Kempf VA (2013) Koch's postulates and the pathogenesis of comparative infectious disease causation associated with *Bartonella* species. J Comp Pathol 148:115–125
 34. Kosoy M, Bai Y, Sheff K, Morway C, Baggett H, Maloney SA, Boonmar S, Bhengsi S, Dowell SF, Sidthirasdr A, Lerdtthusnee K, Richardson J, Peruski LF (2010) Identification of *Bartonella* infections in febrile human patients from Thailand and their potential animal reservoirs. Am J Trop Med Hyg 82(6):1140–1145
 35. McVea DA, Himsforth CG, Patrick DM, Lindsay LR, Kosoy M, Kerr T (2018) Exposure to rats and rat-associated leptospira and bartonella species among people who use drugs in an impoverished, inner-city neighborhood of Vancouver, Canada. Vector Borne Zoonotic Dis 18:82–88
 36. Fernández-González AM, Kosoy MY, Rubio AV, Graham CB, Monteneri JA, Osikowicz LM, Bai Y, Acosta-Gutiérrez R, Ávila-Flores R, Gage KL, Suzán G (2016) Molecular survey of *Bartonella* species and yersinia pestis in rodent fleas (Siphonaptera) from Chihuahua, Mexico. J Med Entomol 53:199–205
 37. Kamani J, Morick D, Mumcuoglu KY, Harrus S (2013) Prevalence and diversity of *Bartonella* species in commensal rodents and ectoparasites from Nigeria, West Africa. PLoS Negl Trop Dis 7:e2246

38. Lei BR, Olival KJ (2014) Contrasting patterns in mammal–bacteria coevolution: bartonella and leptospira in bats and rodents. *PLoS Negl Trop Dis* 8:e2738
39. Breitschwerdt EB, Maggi RG, Sigmon B, Nicholson WL (2007) Isolation of *Bartonella quintana* from a woman and a cat following putative bite transmission. *J Clin Microbiol* 45:270–272
40. Breitschwerdt EB, Mascarelli PE, Schweickert LA, Maggi RG, Hegarty BC, Bradley JM, Woods CW (2011) Hallucinations, sensory neuropathy, and peripheral visual deficits in a young woman infected with *Bartonella koehlerae*. *J Clin Microbiol* 49:3415–3417
41. Pappalardo BL, Correa MT, York CC, Peat CY, Breitschwerdt EB (1997) Epidemiologic evaluation of the risk factors associated with exposure and seroreactivity to *Bartonella vinsonii* in dogs. *Am J Vet Res* 58:467–471